Point of Care Molecular Diagnostics Market by Product & Service (Assays, Kits, Analyzers, Software), Application (Respiratory Disease, Hospital Acquired Infection), Technology (RT-PCR, INAAT), End User (Physician Office, ICUS) - Global Forecast to 2023
“The global POC molecular diagnostics market is projected to grow at a CAGR of 14.7%.”
The global point of care (POC) molecular diagnostics market is expected to reach USD 1440.2 million by 2023 from USD 725.5 million in 2018, at a CAGR of 14.7%. Growth in the POC molecular diagnostics market is driven by the increasing prevalence of infectious diseases, rising focus on decentralized diagnostics, and the growing demand for CLIA-waived molecular POC tests. However, inadequate reimbursement and stringent regulatory policies are likely to restrain the growth of this market during the forecast period.
“The INAAT technology is expected to grow at highest CAGR during the forecast period.”
Based on technology, the POC molecular diagnostics market is segmented into RT-PCR, INAAT, and other technologies. The INAAT segment is expected to grow at highest CAGR during the forecasted period. The increasing popularity of INAAT for infectious diseases diagnosis is expected to drive this market in the coming years.
“Asia Pacific is projected to grow at the highest CAGR during the forecast period.”
While North America is expected to account for the largest share of the global POC molecular diagnostics market, Asia Pacific is projected to grow at the highest CAGR during the study period. The key factors influencing the growth of this market include growing initiatives by market players, rising demand for influenza A/B tests, decentralized healthcare delivery systems, and increasing patient population base in this region.
Break-up profile of primaries:
Research Coverage:
The POC molecular diagnostics market in this report is segmented by product & service, application, technology, end user, and region. The study tracks and analyzes competitive developments such as product launches & approvals, acquisition, collaborations, agreements, partnerships, and expansion, and profiles key players and their core competencies in the POC molecular diagnostics market.
Reasons to buy this report:
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on portfolios offered by the top players in the global POC molecular diagnostics market. The report analyzes the market by product & service, application type, technology, end user, and region
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global POC molecular diagnostics market
Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for POC molecular diagnostic products across regions
Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global POC molecular diagnostics market
Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global POC molecular diagnostics market
The global point of care (POC) molecular diagnostics market is expected to reach USD 1440.2 million by 2023 from USD 725.5 million in 2018, at a CAGR of 14.7%. Growth in the POC molecular diagnostics market is driven by the increasing prevalence of infectious diseases, rising focus on decentralized diagnostics, and the growing demand for CLIA-waived molecular POC tests. However, inadequate reimbursement and stringent regulatory policies are likely to restrain the growth of this market during the forecast period.
“The INAAT technology is expected to grow at highest CAGR during the forecast period.”
Based on technology, the POC molecular diagnostics market is segmented into RT-PCR, INAAT, and other technologies. The INAAT segment is expected to grow at highest CAGR during the forecasted period. The increasing popularity of INAAT for infectious diseases diagnosis is expected to drive this market in the coming years.
“Asia Pacific is projected to grow at the highest CAGR during the forecast period.”
While North America is expected to account for the largest share of the global POC molecular diagnostics market, Asia Pacific is projected to grow at the highest CAGR during the study period. The key factors influencing the growth of this market include growing initiatives by market players, rising demand for influenza A/B tests, decentralized healthcare delivery systems, and increasing patient population base in this region.
Break-up profile of primaries:
- By Company Type- Tier 40%, Tier 30%, and Tier 30%
- By Designation-C-level-27%, D-level-18%, and Others-55%
- By Region-North America-50%, Europe-20%, Asia Pacific-20%, and RoW-10%
Research Coverage:
The POC molecular diagnostics market in this report is segmented by product & service, application, technology, end user, and region. The study tracks and analyzes competitive developments such as product launches & approvals, acquisition, collaborations, agreements, partnerships, and expansion, and profiles key players and their core competencies in the POC molecular diagnostics market.
Reasons to buy this report:
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on portfolios offered by the top players in the global POC molecular diagnostics market. The report analyzes the market by product & service, application type, technology, end user, and region
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global POC molecular diagnostics market
Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for POC molecular diagnostic products across regions
Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global POC molecular diagnostics market
Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global POC molecular diagnostics market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 PRIMARY DATA
2.1.1 KEY DATA FROM PRIMARY SOURCES
2.1.2 KEY INDUSTRY INSIGHTS
2.2 SECONDARY DATA
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4.1 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 POC MOLECULAR DIAGNOSTICS MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: APAC POC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY AND PRODUCT
4.3 POC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
4.4 POC MOLECULAR DIAGNOSTICS MARKET, BY END USER
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing worldwide prevalence of infectious diseases
5.2.1.2 Rising focus on decentralized diagnostics
5.2.1.3 Growing demand for CLIA-waived molecular POC tests
5.2.2 RESTRAINTS
5.2.2.1 Inadequate reimbursements
5.2.2.2 Stringent and time-consuming regulatory policies significantly increase the product launch cycle
5.2.3 OPPORTUNITIES
5.2.3.1 Growing R&D activities in molecular diagnostic testing
5.2.3.2 Increasing penetration of POC molecular diagnostic tests in China, India, and Brazil
6 POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
6.1 INTRODUCTION
6.1.1 RESPIRATORY DISEASES
6.1.2 SEXUALLY TRANSMITTED DISEASES
6.1.3 HOSPITAL-ACQUIRED INFECTIONS
6.1.4 ONCOLOGY
6.1.5 HEPATITIS
6.1.6 OTHER APPLICATIONS
7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 RT-PCR
7.3 INAAT
7.4 OTHER TECHNOLOGIES
8 POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
8.1 INTRODUCTION
8.2 ASSAYS & KITS
8.3 INSTRUMENTS/ANALYZERS
8.4 SOFTWARE & SERVICES
9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHYSICIAN OFFICES
9.3 HOSPITAL EMERGENCY DEPARTMENTS & INTENSIVE CARE UNITS
9.4 RESEARCH INSTITUTES
9.5 OTHER END USERS
10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.4 ASIA PACIFIC
10.5 ROW
11 COMPETITIVE LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET RANKING ANALYSIS, 2017
11.3 COMPETITIVE SITUATION AND TRENDS
11.3.1 PRODUCT LAUNCHES AND APPROVALS
11.3.2 ACQUISITIONS
11.3.3 COLLABORATIONS/AGREEMENTS/PARTNERSHIPS
11.3.4 EXPANSIONS
12 COMPANY PROFILE
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 ABBOTT LABORATORIES
12.2 DANAHER CORPORATION
12.3 BIOMÉRIEUX SA
12.4 ROCHE DIAGNOSTICS
12.5 QUIDEL
12.6 MERIDIAN BIOSCIENCE
12.7 MESA BIOTECH
12.8 GENEPOC
12.9 DXNA
12.10 ATLAS GENETICS
12.11 SPARTAN BIOSCIENCE
12.12 BIOCARTIS
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 PRIMARY DATA
2.1.1 KEY DATA FROM PRIMARY SOURCES
2.1.2 KEY INDUSTRY INSIGHTS
2.2 SECONDARY DATA
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4.1 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 POC MOLECULAR DIAGNOSTICS MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: APAC POC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY AND PRODUCT
4.3 POC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
4.4 POC MOLECULAR DIAGNOSTICS MARKET, BY END USER
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing worldwide prevalence of infectious diseases
5.2.1.2 Rising focus on decentralized diagnostics
5.2.1.3 Growing demand for CLIA-waived molecular POC tests
5.2.2 RESTRAINTS
5.2.2.1 Inadequate reimbursements
5.2.2.2 Stringent and time-consuming regulatory policies significantly increase the product launch cycle
5.2.3 OPPORTUNITIES
5.2.3.1 Growing R&D activities in molecular diagnostic testing
5.2.3.2 Increasing penetration of POC molecular diagnostic tests in China, India, and Brazil
6 POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
6.1 INTRODUCTION
6.1.1 RESPIRATORY DISEASES
6.1.2 SEXUALLY TRANSMITTED DISEASES
6.1.3 HOSPITAL-ACQUIRED INFECTIONS
6.1.4 ONCOLOGY
6.1.5 HEPATITIS
6.1.6 OTHER APPLICATIONS
7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 RT-PCR
7.3 INAAT
7.4 OTHER TECHNOLOGIES
8 POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
8.1 INTRODUCTION
8.2 ASSAYS & KITS
8.3 INSTRUMENTS/ANALYZERS
8.4 SOFTWARE & SERVICES
9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHYSICIAN OFFICES
9.3 HOSPITAL EMERGENCY DEPARTMENTS & INTENSIVE CARE UNITS
9.4 RESEARCH INSTITUTES
9.5 OTHER END USERS
10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.4 ASIA PACIFIC
10.5 ROW
11 COMPETITIVE LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET RANKING ANALYSIS, 2017
11.3 COMPETITIVE SITUATION AND TRENDS
11.3.1 PRODUCT LAUNCHES AND APPROVALS
11.3.2 ACQUISITIONS
11.3.3 COLLABORATIONS/AGREEMENTS/PARTNERSHIPS
11.3.4 EXPANSIONS
12 COMPANY PROFILE
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 ABBOTT LABORATORIES
12.2 DANAHER CORPORATION
12.3 BIOMÉRIEUX SA
12.4 ROCHE DIAGNOSTICS
12.5 QUIDEL
12.6 MERIDIAN BIOSCIENCE
12.7 MESA BIOTECH
12.8 GENEPOC
12.9 DXNA
12.10 ATLAS GENETICS
12.11 SPARTAN BIOSCIENCE
12.12 BIOCARTIS
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
LIST OF TABLES
Table 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2016–2023 (USD MILLION)
Table 3 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2016–2023 (USD MILLION)
Table 5 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ASSOCIATED INFECTIONS, BY REGION, 2016–2023 (USD MILLION)
Table 7 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ASSOCIATED INFECTIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2016–2023 (USD MILLION)
Table 9 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2016–2023 (USD MILLION)
Table 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2016–2023 (USD MILLION)
Table 11 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2016–2023 (USD MILLION)
Table 13 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 14 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2016–2023 (USD MILLION)
Table 16 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2016–2023 (USD MILLION)
Table 17 PRODUCT APPROVALS IN THE LAST THREE YEARS
Table 18 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2016–2023 (USD MILLION)
Table 19 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2016–2023 (USD MILLION)
Table 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016–2023 (USD MILLION)
Table 21 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 23 POC MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2016–2023 (USD MILLION)
Table 24 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 25 POC MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2016–2023 (USD MILLION)
Table 26 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 27 POC MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2016–2023 (USD MILLION)
Table 28 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY REGION, 2016–2023 (USD MILLION)
Table 31 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL EDS & ICUS, BY REGION, 2016–2023 (USD MILLION)
Table 33 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL EDS & ICUS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2016–2023 (USD MILLION)
Table 35 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2016–2023 (USD MILLION)
Table 37 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 39 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 40 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 41 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 42 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 43 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 44 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 45 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 46 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 47 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 48 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 49 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 50 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 51 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 52 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 53 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 54 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 55 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 56 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2023 (USD MILLION)
Table 57 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 58 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 59 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 60 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2023 (USD MILLION)
Table 61 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 62 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 63 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 64 RANK OF COMPANIES IN THE GLOBAL MOLECULAR POC DIAGNOSTIC MARKET, 2017
Table 65 PRODUCT LAUNCHES, 2015-2018
Table 66 ACQUISITIONS, 2015-2018
Table 67 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS, 2015 & 2018
Table 68 EXPANSIONS, 2015 TO 2018
Table 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2016–2023 (USD MILLION)
Table 3 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2016–2023 (USD MILLION)
Table 5 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ASSOCIATED INFECTIONS, BY REGION, 2016–2023 (USD MILLION)
Table 7 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ASSOCIATED INFECTIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2016–2023 (USD MILLION)
Table 9 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2016–2023 (USD MILLION)
Table 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2016–2023 (USD MILLION)
Table 11 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2016–2023 (USD MILLION)
Table 13 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 14 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2016–2023 (USD MILLION)
Table 16 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2016–2023 (USD MILLION)
Table 17 PRODUCT APPROVALS IN THE LAST THREE YEARS
Table 18 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2016–2023 (USD MILLION)
Table 19 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2016–2023 (USD MILLION)
Table 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016–2023 (USD MILLION)
Table 21 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 23 POC MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2016–2023 (USD MILLION)
Table 24 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 25 POC MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2016–2023 (USD MILLION)
Table 26 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 27 POC MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2016–2023 (USD MILLION)
Table 28 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY REGION, 2016–2023 (USD MILLION)
Table 31 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL EDS & ICUS, BY REGION, 2016–2023 (USD MILLION)
Table 33 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL EDS & ICUS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2016–2023 (USD MILLION)
Table 35 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2016–2023 (USD MILLION)
Table 37 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 39 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 40 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 41 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 42 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 43 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 44 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 45 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 46 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 47 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 48 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 49 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 50 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 51 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 52 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
Table 53 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 54 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 55 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 56 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2023 (USD MILLION)
Table 57 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 58 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 59 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 60 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2023 (USD MILLION)
Table 61 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 62 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 63 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 64 RANK OF COMPANIES IN THE GLOBAL MOLECULAR POC DIAGNOSTIC MARKET, 2017
Table 65 PRODUCT LAUNCHES, 2015-2018
Table 66 ACQUISITIONS, 2015-2018
Table 67 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS, 2015 & 2018
Table 68 EXPANSIONS, 2015 TO 2018
LIST OF FIGURES
Figure 1 RESEARCH DESIGN
Figure 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 5 DATA TRIANGULATION
Figure 6 POC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018 VS. 2023
Figure 7 POC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018 VS. 2023
Figure 8 POC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018 VS. 2023
Figure 9 NORTH AMERICA TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET IN 2018
Figure 10 INCREASING WORLDWIDE PREVALENCE OF INFECTIOUS DISEASES, A KEY DRIVER FOR THE GROWTH OF THE POC MOLECULAR DIAGNOSTICS MARKET
Figure 11 ASSAYS & KITS TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET IN ASIA PACIFIC IN 2017
Figure 12 RESPIRATORY DISEASES TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
Figure 13 PHYSICIAN OFFICES TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
Figure 14 POC MOLECULAR DIAGNOSTIC MARKET: DRIVERS, RESTRAINTS, & OPPORTUNITIES
Figure 15 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
Figure 16 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
Figure 17 ABBOTT LABORATORIES: COMPANY SNAPSHOT ( 2017)
Figure 18 DANAHER CORPORATION: COMPANY SNAPSHOT (2017)
Figure 19 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2017)
Figure 20 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017)
Figure 21 QUIDEL: COMPANY SNAPSHOT (2016)
Figure 22 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2017)
Figure 23 BIOCARTIS: COMPANY SNAPSHOT (2017)
Figure 1 RESEARCH DESIGN
Figure 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 5 DATA TRIANGULATION
Figure 6 POC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018 VS. 2023
Figure 7 POC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018 VS. 2023
Figure 8 POC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018 VS. 2023
Figure 9 NORTH AMERICA TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET IN 2018
Figure 10 INCREASING WORLDWIDE PREVALENCE OF INFECTIOUS DISEASES, A KEY DRIVER FOR THE GROWTH OF THE POC MOLECULAR DIAGNOSTICS MARKET
Figure 11 ASSAYS & KITS TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET IN ASIA PACIFIC IN 2017
Figure 12 RESPIRATORY DISEASES TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
Figure 13 PHYSICIAN OFFICES TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
Figure 14 POC MOLECULAR DIAGNOSTIC MARKET: DRIVERS, RESTRAINTS, & OPPORTUNITIES
Figure 15 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
Figure 16 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
Figure 17 ABBOTT LABORATORIES: COMPANY SNAPSHOT ( 2017)
Figure 18 DANAHER CORPORATION: COMPANY SNAPSHOT (2017)
Figure 19 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2017)
Figure 20 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017)
Figure 21 QUIDEL: COMPANY SNAPSHOT (2016)
Figure 22 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2017)
Figure 23 BIOCARTIS: COMPANY SNAPSHOT (2017)
